Literature DB >> 22018861

Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis.

Sabine Wagnerberger1, Astrid Spruss, Giridhar Kanuri, Valentina Volynets, Carolin Stahl, Stephan C Bischoff, Ina Bergheim.   

Abstract

Studies in animals and human subjects indicate that gut-derived bacterial endotoxins may play a critical role in the development of non-alcoholic fatty liver disease (NAFLD). In the present study, we investigated if the liver is also sensitised by other microbial components during the onset of fructose-induced steatosis in a mouse model. C57BL/6 mice were either fed with 30 % fructose solution or tap water (control) with or without antibiotics for 8 weeks. Expression of toll-like receptors (TLR)1-9, TNF-α, inducible NO synthase (iNOS), myeloid differentiation factor 88 (MyD88) and number of F4/80 positive cells in the liver were assessed. Occludin protein, DNA of microbiota in the small and large intestine and retinol binding protein 4 (RBP4) in plasma were analysed using Western blot, DNA fingerprinting and ELISA, respectively. F4/80 positive cells were determined by immunohistochemistry. The accumulation of TAG found in the livers of fructose-fed mice was associated with a significant induction of TLR 1-4 and 6-8. Plasma RBP4 concentration and hepatic mRNA expression levels of TNF-α, iNOS, MyD88 and number of F4/80 positive cells of fructose-fed animals were significantly higher than those of controls; however, these effects of fructose were attenuated in antibiotic-treated mice. Whereas protein concentration of occludin was lower in the duodenum of fructose-treated mice, no systematic alterations of microbiota were found in this part of the intestine. Taken together, these data support the hypothesis that (1) an increased intestinal translocation of microbial components and (2) an increased number of F4/80 positive cells and induction of several TLR and dependent pathways (e.g. MyD88 and iNOS) may be involved in the onset of fructose-induced NAFLD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018861     DOI: 10.1017/S0007114511004983

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  41 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.

Authors:  Veerle Bieghs; Christian Trautwein
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

3.  Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis.

Authors:  Tatsuhiro Tsujimoto; Hideto Kawaratani; Toshiyuki Kitazawa; Masahito Uemura; Hiroshi Fukui
Journal:  Dig Dis Sci       Date:  2012-02-25       Impact factor: 3.199

4.  Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD).

Authors:  Cathrin Sellmann; Cheng Jun Jin; Anna Janina Engstler; Jean-Pascal De Bandt; Ina Bergheim
Journal:  Eur J Nutr       Date:  2016-08-05       Impact factor: 5.614

5.  Gut microbiota, fatty liver disease, and hepatocellular carcinoma.

Authors:  Huikuan Chu; Brandon Williams; Bernd Schnabl
Journal:  Liver Res       Date:  2018-02-21

6.  Effect of acute beer ingestion on the liver: studies in female mice.

Authors:  Giridhar Kanuri; Sabine Wagnerberger; Marianne Landmann; Eva Prigl; Claus Hellerbrand; Stephan C Bischoff; Ina Bergheim
Journal:  Eur J Nutr       Date:  2014-06-15       Impact factor: 5.614

Review 7.  Animal Models Correlating Immune Cells for the Development of NAFLD/NASH.

Authors:  Srikanth Iyer; Pramod Kumar Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  J Clin Exp Hepatol       Date:  2015-07-09

Review 8.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 9.  Microbiota-liver axis in hepatic disease.

Authors:  Benoit Chassaing; Lucie Etienne-Mesmin; Andrew T Gewirtz
Journal:  Hepatology       Date:  2013-11-15       Impact factor: 17.425

Review 10.  Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease.

Authors:  Pietro Vajro; Giulia Paolella; Alessio Fasano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-05       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.